| Astellas and Theravance Announce European Marketing Authorization for VIBATIV ... - MarketWatch (press release) |
|
|
MarketWatch (press release) New onset or worsening renal impairment occurred in patients who received VIBATIV(R). Renal adverse events were more likely to occur in patients with baseline comorbidities known to predispose patients to kidney dysfunction and in patients who received |